Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306

BACKGROUND: This randomised phase II/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior to the standard Adriamycin plus ifosfamide (AI) in terms of overall survival (OS) in patients with soft tissue sarcoma (STS). METHODS: Patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Kazuhiro, Machida, Ryunosuke, Kawai, Akira, Nakayama, Robert, Tsukushi, Satoshi, Asanuma, Kunihiro, Matsumoto, Yoshihiro, Hiraga, Hiroaki, Hiraoka, Koji, Watanuki, Munenori, Yonemoto, Tsukasa, Abe, Satoshi, Katagiri, Hirohisa, Nishida, Yoshihiro, Nagano, Akihito, Suehara, Yoshiyuki, Kawashima, Hiroyuki, Kawano, Masanori, Morii, Takeshi, Hatano, Hiroshi, Toguchida, Junya, Okuma, Tomotake, Takeyama, Masanobu, Takenaka, Satoshi, Akisue, Toshihiro, Furuta, Taisuke, Emori, Makoto, Hiruma, Toru, Outani, Hidetatsu, Yamamoto, Tetsuji, Kataoka, Tomoko, Fukuda, Haruhiko, Ozaki, Toshifumi, Iwamoto, Yukihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553903/
https://www.ncbi.nlm.nih.gov/pubmed/35871234
http://dx.doi.org/10.1038/s41416-022-01912-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553903/
https://www.ncbi.nlm.nih.gov/pubmed/35871234
http://dx.doi.org/10.1038/s41416-022-01912-5

Ejemplares similares